DuPont Net-Zero Climate Targets Validated by Science Based Targets initiative

SBTi validation recognizes DuPont's continued climate progress, with new 2035 emissions-reduction targets and a 2050 net-zero target WILMINGTON, Del., Oct. 29, 2026 /PRNewswire/ -- DuPont (NYSE: DD) today announced that its net-zero science-based greenhouse gas (GHG) emissions reduction targets have been validated by the Science Based Targets initiative (SBTi).

PRNewsWire • 11 hours ago

4 Chemical Stocks Set to Pull Off a Beat This Earnings Season

A recovery in end-market demand and self-help measures, including cost cuts and productivity gains, position AVNT, APD, DD, and HUN to beat Q3 earnings estimates.

Zacks Investment Research • 10 hours ago

duPont REGISTRY Group to Showcase Lineup of Supercars at Concours at Wynn Las Vegas

MIAMI--(BUSINESS WIRE)--duPont REGISTRY Group to Showcase Lineup of Supercars at Concours at Wynn Las Vegas.

Business Wire • 12 hours ago

5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps

The S&P 500 recently sat just 2.5% below its all-time high. Look past the index, though, and the picture gets uglier.

MarketBeat • Oct 26, 2026

DuPont Expands Bioprocessing Portfolio With New Chromatography Media

DD expands its bioprocessing portfolio with AmberChrom SIL silica gel, targeting high-purity peptide purification amid growing demand for GLP-1 therapeutics.

Zacks Investment Research • Oct 23, 2026

DuPont Launches AmberChrom™ SIL Silica Gel for Chromatography to Advance Manufacturing of GLP-1 and Other Peptide Therapeutics

New silica-based chromatography media helps biopharmaceutical manufacturers achieve demanding purity targets while supporting integrated purification workflows from crude purification through final polishing WILMINGTON, Del., Oct. 22, 2026 /PRNewswire/ -- DuPont (NYSE: DD) today announced the launch of DuPont™ AmberChrom™ SIL silica gel, a new reverse phase silica-based solution designed to support the purification and manufacture of peptide therapeutics, including glucagon-like peptide-1 ( GLP-1 ) receptor agonists.

PRNewsWire • Oct 22, 2026

A 30.9% Yield Looks Incredible. The Dividend Math Tells Another Story

Six industrial giants are selling off divisions while keeping payouts high, and the cash flow numbers behind those yields tell a very different story than the headline percentages suggest.

24/7 Wall Street • Oct 20, 2026

DD Gains on Innovation, Productivity and Strategic Acquisitions

DuPont's innovation investments, healthcare acquisitions and productivity gains support growth as it raises 2026 earnings guidance amid persistent cost pressures.

Zacks Investment Research • Oct 19, 2026

DuPont Announces Regular Quarterly Dividend on Common Stock

WILMINGTON, Del., Oct. 13, 2026 /PRNewswire/ -- DuPont (NYSE: DD) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the outstanding Common Stock of the Company (par value $0.01 per share) payable on December 15, 2026, to holders of record of said stock at the close of business on November 30, 2026.

PRNewsWire • Oct 13, 2026

DuPont Schedules Third Quarter 2026 Earnings Conference Call

WILMINGTON, Del., Oct. 6, 2026 /PRNewswire/ -- DuPont (NYSE: DD) will release its third quarter 2026 financial results at 6:00 a.m.

PRNewsWire • Oct 6, 2026